Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Hyperion Pricing On Ravicti Will Test Premium For Convenience In Orphan Market

This article was originally published in The Pink Sheet Daily

Executive Summary

Ravicti’s price tag is $250,000 to $290,000 per year while the upper WAC price for Valeant’s competing product Buphenyl is roughly $240,000 at the maximum dose; Hyperion has option to acquire Buphenyl.

You may also be interested in...



Hyperion Cuts Its Losses After Andromeda Deception

The biotech revealed that its recently closed acquisition was conducted under false pretenses and that Andromeda employees had been manipulating clinical trial data for the late-stage type 1 diabetes drug.

Deal Watch: Much Activity Beyond GSK/Novartis/Lilly Pacts And Valeant/Allergan Bid

In addition to the mega-deal, Valeant’s latest acquisition gambit and the Pfizer/AstraZeneca rumors, the hectic week saw Celgene pay a huge upfront for a Phase III Crohn’s candidate, Aastrom purchase Sanofi’s regenerative medicine business and The Medicines Company add to its surgical products portfolio.

Hyperion Revealed As Andromeda’s Mystery Buyer In $570M Deal

The California biotech is adding to its orphan drug roster with the purchase of the Israeli biotech and its late-stage type 1 diabetes treatment in a back-loaded deal that leaves little room for risk.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS075365

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel